Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is engaged in discovering, inventing, developing, manufacturing, and commercializing medicines for treating various diseases. Analyst John Newman ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops medicines to treat serious diseases. It manufactures and sells treatments for conditions like eye diseases ...

Rockland County Executive Ed Day's 2025 State of the County Address highlighted a list of achievements during ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Is Regeneron Pharmaceuticals, Inc. (REGN) a Promising Biotech Stocks According to Wall Street Analysts A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe ...

San Francisco, California--(Newsfile Corp. - March 3, 2025) - Biotechnology giant Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is embroiled in a securities class action lawsuit, alleging the ...

SAN FRANCISCO, March 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing headwinds on multiple fronts, including disappointing sales figures, ongoing legal ...

Good morning, everyone. Tyler Van Buren here, senior biotech analyst at TD Cowen. Welcome again, and thank you very much for joining TD Cowen's 45th Annual Healthcare Conference. For our next ...